CSIMarket


Clearside Biomedical Inc   (CLSD)
Other Ticker:  
 


 

Clearside Biomedical Inc

CLSD's Financial Statements and Analysis



Clearside Biomedical Inc increased third quarter of 2023 net loss per share of $-0.15 compare to net loss per share of $-0.13 recorded in the same quarter a year ago a decrease compare to $-0.15 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.15 $  1 Mill
$-0.02     $+1M     +222.93 %



Clearside Biomedical Inc 's Revenue rose by 222.93 % in third quarter of 2023 (Sep 30 2023) year on year, to $1 million and declined by -15.62 % sequentially.


Clearside Biomedical Inc is

More on CLSD's Income Statement



Clearside Biomedical Inc 's in thethird quarter of 2023 recorded net loss of $-9.267 million, an increase from net loss of $-7.827 million in III. Quarter a year ago.

Sequentially net loss advanced

More on CLSD's Growth

Clearside Biomedical Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-6 million, capital expenditures fell by -0.155187.10%, to $0 millions compare to same quarter a year ago

More on CLSD's Cash flow Statement


Clearside Biomedical Inc does not pay out common stock dividend.

In trailing twelve-month period Clearside Biomedical Inc payed $ -0.39 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -0.21 per share from $ -0.08.

Company issued 0.33 million shares or 0.53 % in Sep 30 2023.


More on CLSD's Dividends

 Market Capitalization (Millions) 105
 Shares Outstanding (Millions) 62
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) -2
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Clearside Biomedical Inc does not pay out common stock dividend.

In trailing twelve-month period Clearside Biomedical Inc had negative $ -0.39 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -0.21 per share from $ -0.08.

Company issued 0.33 million shares or 0.53 % in Sep 30 2023.


More on CLSD's Balance Sheets

 Market Capitalization (Millions) 105
 Shares Outstanding (Millions) 62
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) -2
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Clearside Biomedical Inc Earnings

Clearside Biomedical Inc. Struggles to Attain Profitability Despite Exponential Revenue Growth in Q3 of 2023

Clearside Biomedical Inc's recent announcement of very solid revenue growth of 222.932% year on year may seem impressive at...

Clearside Biomedical Inc's Impressive Revenue Growth Masks Concerns Over Diminishing Returns and Net Deficit



Clearside Biomedical Inc (NASDAQ: CLSD) has recently announced an impressive revenue growth rate of 165.104% year-on-year, reaching $1.02 million for the three-month period ending on June 30, 2023. While this growth is undoubtedly positive news for the company, there are some concerning factors surrounding diminishing returns. This article will delve into Clearside Biomedical's latest financial performance, its net deficit, and the current state of its stock.
1. Revenue Growth:
Clearside Biomedical Inc's revenue surge of 165.104% year-on-year is undoubtedly admirable. It indicates that the company's products or services have gained traction in the market, attracting more customers and gener...

Clearside Biomedical Inc Faces Alarming Losses with Revenue Plummeting to $0.00 Million

In the latest blow to the pharmaceutical industry, Clearside Biomedical Inc has posted alarming losses in its most recent fiscal period. According to the company's disclosure, its revenue has taken a significant plunge, dropping to $0.00 million overall. Furthermore, there was an increased net deficit per share to $-0.15, which is a worrying trend compared to the similar reporting season a year ago. This marks a decline from the previous period, where the company posted $-0.16 per share and $0.33 million in revenue.
The numbers are even bleaker when we look at the period between January to March 31, 2023. That time-frame saw a massive net loss of $-9.280 million, which is a troubling increase from $-7.64...


Date modified: 2023-11-14T21:42:13+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com